Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks

A lock solution composed of gentamicin sulfate (5 mg/mL) and ethylenediaminetetraacetic acid disodium salt (EDTA-Na2, 30 mg/mL) could fully eradicate in vivo bacterial biofilms in totally implantable venous access ports (TIVAP). In this study, fabrication, conditioning and sterilization processes of...

Full description

Bibliographic Details
Main Authors: Anne-Sophie Fiolet, Elise Jandot, Pauline Doucey, Coralie Crétet, Célia Brunel, Christine Pivot, Jean-Marc Ghigo, Christophe Beloin, David Lebeaux, Fabrice Pirot
Format: Article
Language:English
Published: Elsevier 2018-12-01
Series:Journal of Pharmaceutical Analysis
Online Access:http://www.sciencedirect.com/science/article/pii/S2095177917301132
id doaj-6cbe9842df634b47b03fa79956fd031e
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Anne-Sophie Fiolet
Elise Jandot
Pauline Doucey
Coralie Crétet
Célia Brunel
Christine Pivot
Jean-Marc Ghigo
Christophe Beloin
David Lebeaux
Fabrice Pirot
spellingShingle Anne-Sophie Fiolet
Elise Jandot
Pauline Doucey
Coralie Crétet
Célia Brunel
Christine Pivot
Jean-Marc Ghigo
Christophe Beloin
David Lebeaux
Fabrice Pirot
Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks
Journal of Pharmaceutical Analysis
author_facet Anne-Sophie Fiolet
Elise Jandot
Pauline Doucey
Coralie Crétet
Célia Brunel
Christine Pivot
Jean-Marc Ghigo
Christophe Beloin
David Lebeaux
Fabrice Pirot
author_sort Anne-Sophie Fiolet
title Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks
title_short Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks
title_full Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks
title_fullStr Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks
title_full_unstemmed Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks
title_sort long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (edta-na2) solution for catheter locks
publisher Elsevier
series Journal of Pharmaceutical Analysis
issn 2095-1779
publishDate 2018-12-01
description A lock solution composed of gentamicin sulfate (5 mg/mL) and ethylenediaminetetraacetic acid disodium salt (EDTA-Na2, 30 mg/mL) could fully eradicate in vivo bacterial biofilms in totally implantable venous access ports (TIVAP). In this study, fabrication, conditioning and sterilization processes of antimicrobial lock solution (ALS) were detailed and completed by a stability study. Stability of ALS was conducted for 12 months in vial (25 °C ± 2 °C, 60% ± 5% relative humidity (RH), and at 40 °C ± 2 °C, RH 75% ± 5%) and for 24 h and 72 h in TIVAP (40 °C ± 2 °C, RH 75% ± 5%). A stability indicating HPLC assay with UV detection for simultaneous quantification of gentamicin sulfate and EDTA-Na2 was developed. ALS was assayed by ion-pairing high performance liquid chromatography (HPLC) needing gentamicin derivatization, EDTA-Na2 metallocomplexation of samples and gradient mobile phase. HPLC methods to separate four gentamicin components and EDTA-Na2 were validated. Efficiency of sterility procedure and conditioning of ALS was confirmed by bacterial endotoxins and sterility tests. Physicochemical stability of ALS was determined by visual inspection, osmolality, pH, and sub-visible particle counting. Results confirmed that the stability of ALS in vials was maintained for 12 months and 24 h and 72 h in TIVAP. Keywords: Gentamicin-EDTA-Na2 loaded antimicrobial lock solution, Pharmaceutical compounding, Stability indicating HPLC assay method, Totally implantable venous access ports
url http://www.sciencedirect.com/science/article/pii/S2095177917301132
work_keys_str_mv AT annesophiefiolet longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks
AT elisejandot longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks
AT paulinedoucey longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks
AT coraliecretet longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks
AT celiabrunel longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks
AT christinepivot longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks
AT jeanmarcghigo longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks
AT christophebeloin longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks
AT davidlebeaux longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks
AT fabricepirot longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks
_version_ 1724171338889822208
spelling doaj-6cbe9842df634b47b03fa79956fd031e2021-04-02T07:14:44ZengElsevierJournal of Pharmaceutical Analysis2095-17792018-12-0186386393Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locksAnne-Sophie Fiolet0Elise Jandot1Pauline Doucey2Coralie Crétet3Célia Brunel4Christine Pivot5Jean-Marc Ghigo6Christophe Beloin7David Lebeaux8Fabrice Pirot9Service Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceUnité de Génétique des Biofilms, Département de Microbiologie, Institut Pasteur, 28 rue du docteur Roux, F-75724 Paris Cedex 15, FranceUnité de Génétique des Biofilms, Département de Microbiologie, Institut Pasteur, 28 rue du docteur Roux, F-75724 Paris Cedex 15, FranceUnité de Génétique des Biofilms, Département de Microbiologie, Institut Pasteur, 28 rue du docteur Roux, F-75724 Paris Cedex 15, France; Service de Microbiologie, Unité Mobile de Microbiologie Clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France; Université Paris Descartes, 12 rue de l′Ecole de Médecine, 75270 Paris Cedex 06, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, France; Laboratoire de Recherche et Développement de Pharmacie Galénique Industrielle, UMR 5305, Plateforme FRIPHARM,F-69373, Faculté de Pharmacie, Université Claude Bernard Lyon 1, 8, avenue Rockefeller, F-69373 Lyon Cedex 08, France; Corresponding author at: Service Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, France.A lock solution composed of gentamicin sulfate (5 mg/mL) and ethylenediaminetetraacetic acid disodium salt (EDTA-Na2, 30 mg/mL) could fully eradicate in vivo bacterial biofilms in totally implantable venous access ports (TIVAP). In this study, fabrication, conditioning and sterilization processes of antimicrobial lock solution (ALS) were detailed and completed by a stability study. Stability of ALS was conducted for 12 months in vial (25 °C ± 2 °C, 60% ± 5% relative humidity (RH), and at 40 °C ± 2 °C, RH 75% ± 5%) and for 24 h and 72 h in TIVAP (40 °C ± 2 °C, RH 75% ± 5%). A stability indicating HPLC assay with UV detection for simultaneous quantification of gentamicin sulfate and EDTA-Na2 was developed. ALS was assayed by ion-pairing high performance liquid chromatography (HPLC) needing gentamicin derivatization, EDTA-Na2 metallocomplexation of samples and gradient mobile phase. HPLC methods to separate four gentamicin components and EDTA-Na2 were validated. Efficiency of sterility procedure and conditioning of ALS was confirmed by bacterial endotoxins and sterility tests. Physicochemical stability of ALS was determined by visual inspection, osmolality, pH, and sub-visible particle counting. Results confirmed that the stability of ALS in vials was maintained for 12 months and 24 h and 72 h in TIVAP. Keywords: Gentamicin-EDTA-Na2 loaded antimicrobial lock solution, Pharmaceutical compounding, Stability indicating HPLC assay method, Totally implantable venous access portshttp://www.sciencedirect.com/science/article/pii/S2095177917301132